Interleukin-35 gene therapy exacerbates experimental rheumatoid arthritis in mice

Cytokine

Volumn 69, Issue 1, 2014, Pages 87-93

  Thiolat, A ^a,b,e,f   Denys, A ^a,b   Petit, M ^a,b   Biton, J ^a,b,g   Lemeiter, D ^a,b   Herve, R ^a,b   Lutomski, D ^c   Boissier, M C ^a,b,d   Bessis, N ^a,b  

^a Institut National de la Recherche Agronomique   (France)

^b UNIVERSITÉ PARIS 13   (France)

^c Laboratory Educations and Health Practices   (France)

^d AVICENNE HOSPITAL   (France)

^e INSERM U955   (France)

^f HENRI MONDOR HOSPITAL   (France)

^g CENTRE DE RECHERCHE DES CORDELIERS   (France)

Author keywords

Gene therapy; Interleukin 35; Regulatory T cells; Rheumatoid arthritis

Indexed keywords

INTERLEUKIN 35; L SELECTIN; COLLAGEN; INTERLEUKIN DERIVATIVE; INTERLEUKIN-35, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; ELECTROPORATION; IL 35 GENE; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE; MALE; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; SPLEEN; TH17 CELL; ANIMAL; BIOSYNTHESIS; CHEMICALLY INDUCED; DBA MOUSE; DISEASE MODEL; EXPERIMENTAL ARTHRITIS; GENE THERAPY; GENE TRANSFER; GENETICS; IMMUNOLOGY; INFLAMMATION; PATHOLOGY; PROCEDURES;

ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; COLLAGEN; DISEASE MODELS, ANIMAL; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; INFLAMMATION; INTERLEUKINS; L-SELECTIN; MICE; MICE, INBRED DBA; T-LYMPHOCYTES, REGULATORY; TH17 CELLS;

EID: 84902195117     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2014.05.015     Document Type: Article

References (24)

1. McInnes I., Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011, 365:2205-2224.
2. Feldmann M., Maini R.N. The role of cytokines in the pathogenesis of rheumatoid arthritis. Rheumatology 1999, 38(Suppl 2):3-7.
3. Adriaansen J., Vervoordeldonk M.J., Tak P.P. Gene therapy as a therapeutic approach for the treatment of rheumatoid arthritis: innovative vectors and therapeutic genes. Rheumatology 2006.
4. Bessis N., Boissier M.C. Gene therapy for patients with rheumatoid arthritis. Jt Bone Spine 2006, 73:169-176.
5. Saidenberg-Kermanach N., Bessis N., Deleuze V., Bureau M., Scherman D., Boissier M.-C. Efficacy of interleukin-10 gene electrotransfer into skeletal muscle in mice with collagen-induced arthritis. J Gene Med 2003, 5:164-171.
6. Bloquel C., Bessis N., Boissier M.C., Scherman D., Bigey P. Gene therapy of collagen-induced arthritis by electrotransfer of human tumor necrosis factor-alpha soluble receptor I variants. Hum Gene Ther 2004, 15:189-201.
7. Denys A., Thiolat A., Descamps D., Lemeiter D., Benihoud K., Bessis N., et al. Intra-articular electrotransfer of mouse soluble tumour necrosis factor receptor in a murine model of rheumatoid arthritis. J Gene Med 2010, 12:659-668.
8. Collison L., Workman C., Kuo T., Boyd K., Wang Y., Vignali K., et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007, 450:566-575.
9. Collison L., Chaturvedi V., Henderson A., Giacomin P., Guy C., Bankoti J., et al. IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol 2010, 11:1093-1194.
10. Bettini M., Castellaw A.H., Lennon G.P., Burton A.R., Vignali D.A.A. Prevention of autoimmune diabetes by ectopic pancreatic β-cell expression of interleukin-35. Diabetes 2012, 61:1519-1526.
11. Wirtz S., Billmeier U., Mchedlidze T., Blumberg R.S., Neurath M.F. Interleukin-35 mediates mucosal immune responses that protect against t-cell-dependent colitis. Gastroenterology 2011, http://dx.doi.org/10.1053/j.gastro.2011.07.040.
12. Niedbala W., Wei X.Q., Cai B., Hueber A.J., Leung B.P., McInnes I.B., et al. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol 2007, 37:3021-3029.
13. Kochetkova I., Golden S., Holderness K., Callis G., Pascual D.W. IL-35 stimulation of CD39+ regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10. J Immunol 2010, 184:7144-7153.
14. Clavel G., Valvason C., Yamaoka K., Lemeiter D., Laroche L., Boissier M.C., et al. Relationship between angiogenesis and inflammation in experimental arthritis. Eur Cytokine Netw 2006, 17:202-210.
15. Vasconcellos R., Carter N.A., Rosser E.C., Mauri C. IL-12p35 subunit contributes to autoimmunity by limiting IL-27-driven regulatory responses. J Immunol 2011, 187:3402-3412.
16. Kuo J., Nardelli D., Warner T., Callister S., Schell R. Interleukin-35 enhances Lyme arthritis in Borrelia-vaccinated and -infected mice. Clin Vaccine Immunol 2011, 18:1125-1157.
17. Senolt L., Filková M., Hulejová H., Cerezo L.A., Pecha O., Plestilová L., et al. Decrease of serum IL-35 predicts clinical improvement in patients with very early RA. Ann Rheum Dis 2011, 70:53.
18. Niu Q, Cai B, Huang Z-C, Shi Y-Y, Wang L-L. Disturbed Th17/Treg balance in patients with rheumatoid arthritis. Rheumatol Int. doi:10.1007/s00296-011-1984-x.
19. Hirota K., Hashimoto M., Yoshitomi H., Tanaka S., Nomura T., Yamaguchi T., et al. T cell self-reactivity forms a cytokine milieu for spontaneous development of IL-17+ Th cells that cause autoimmune arthritis. J Exp Med 2007, 204:41-47.
20. Duarte J., Agua-Doce A., Oliveira V.G., Fonseca J.E., Graca L. Modulation of IL-17 and Foxp3 expression in the prevention of autoimmune arthritis in mice. PLoS One 2010, 5:e10558.
21. Samson M., Audia S., Janikashvili N., Ciudad M., Trad M., Fraszczak J., et al. Brief report: inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis. Arthritis Rheum 2012, 64:2499-2503.
22. Thiolat A., Semerano L., Pers Y.M., Biton J., Lemeiter D., Portales P., et al. Interleukin-6 receptor blockade enhances CD39+ regulatory T cell development in rheumatoid arthritis and in experimental arthritis. Arthritis Rheumatol 2014, 66:273-283.
23. Hiroto Y., Misato H., Masahiko M. IL-6 blockade preferentially inhibits Th17 differentiation in collagen-induced arthritis. Rheumatol Int 2010, 10.1007/s00296-010-1552-.
24. Ermann J., Hoffmann P., Edinger M., Dutt S., Blankenberg F.G., Higgins J.P., et al. Only the CD62L+ subpopulation of CD4+ CD25+ regulatory T cells protects from lethal acute GVHD. Blood 2005, 105:2220-2226.